Please assess the completion status of the following clinical trial:

Trial Title: A Clinical Proof-of-principle Trial in Adult Subjects With Newly Diagnosed Type 1 Diabetes Mellitus Investigating the Effect of NNC0114-0006 and Liraglutide on Preservation of Beta-cell Function

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Informed consent obtained before any trial-related activities. Trial-related activities are any procedures that are carried out as part of the trial, including activities to determine suitability for the trial~* T1DM (type 1 diabetes mellitus) (as diagnosed clinically) for not more than 20 weeks prior to screening - Male or female, aged 18-45 (both inclusive) at the time of signing the informed consent form~* Non-fasting peak C-peptide higher or equal to 0.2 nmol/l at visit 2~* BMI (body mass index) higher or equal to 18.5 kg/m\^2~* Presence of one or more islet specific auto antibodies (glutamic acid decarboxylase (GAD), islet antigen-2 (IA2) or zinc-transporter 8 (ZnT8)) at screening~* Insulin dependence unless in temporary spontaneous remission (honeymoon period)~Exclusion Criteria:~* Daily insulin usage above 1 U/kg per day at screening or use of continuous subcutaneous insulin infusion (CSII)~* History of recurrent (e.g. several times a year) of severe (e.g. pneumonia) or chronic infections or conditions predisposing to chronic infections (e.g., bronchiectasis and chronic osteomyelitis)~* History of severe systemic fungal infection within the past 12 months prior to screening unless treated and resolved with appropriate documented therapy~* Vaccination within 4 weeks before randomisation, Visit 3 (V3)~* Receipt of any other concomitant medications or herbal products that can influence the immune system within 90 days prior to screening (V1)~* History of pancreatitis (acute or chronic)~* Family or personal history of Multiple Endocrine Neoplasia Type 2 (MEN2) or Medullary Thyroid Carcinoma (MTC)~* Any past or current diagnosis of malignant neoplasms~* Known impairment of the immune system, except for T1DM, coeliac disease, alopecia, autoimmune antibodies not considered clinical important (e.g. thyroid antibodies without any clinically important thyroid disease), and vitiligo

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- NNC0114-0006 + Liraglutide (Type: EXPERIMENTAL): None
- NNC0114-0006 + Placebo (Type: EXPERIMENTAL): None
- Liraglutide + Placebo (Type: ACTIVE_COMPARATOR): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).